AstraZeneca’s extended-release drug Bydureon/Bydureon BCise, or exenatide, has gained FDA approval to treat pediatric patients with type 2 diabetes aged 10 years and older. The two Bydureon products differ in mixing procedure and delivery device.
Full Story: Medscape (free registration) (7/23)